Skip to content
OpenCapital
Get started

Veracyte VCYT Enterprise value

Enterprise value at other companies

Guardant Health logo
Guardant HealthGH
$12.72B+121%
Natera, Inc. logo
Natera, Inc.NTRA
$27.5B+49.9%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$8B+4.2%
Revvity logo
RevvityRVTY
$12.88B-13.7%
Labcorp Holdings logo
Labcorp HoldingsLH
$28.24B+10.2%
Quest Diagnostics logo
Quest DiagnosticsDGX
$27.54B+9.5%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.28B+10.7%
P/E48.6×-68.3×
P/S7.9×-0.4×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0×0.0×
Current ratio9.3×+4.2×

Where this comes from

Calculated from Veracyte’s reported figures.

$2.6Bmarket cap+$39.3Mtotal debt−$264.8Mcash and equivalents=$2.33B

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's enterprise value?
Veracyte (VCYT) reported enterprise value of $2.33B in Q1 2026.
How has Veracyte's enterprise value changed year-over-year?
Veracyte's enterprise value increased by 7.4% year-over-year, from $2.17B to $2.33B.
What is the long-term trend for Veracyte's enterprise value?
Over 5 years (2020 to 2025), Veracyte's enterprise value has grown at a -0.9% compound annual growth rate (CAGR), from $3.14B to $3B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.